The concept of evergreening refers to a strategy used by pharmaceutical companies to extend the life of patent protection beyond the term of one or more “original” patents. Companies often ...

Evergreening is when brand-name pharmaceutical companies patent "new inventions" that are in reality minor modifications of old drugs. These could include new forms of release, new dosages ...

Put simply, evergreening is when a pharma company patents minor modifications on the drug as “new inventions” and then uses the new patents to extend their monopoly, freezing out competition ...

India’s offer comes in the backdrop of the US administration’s stated desire to sharply reduce local drug prices, and gains ...

To delay the “patent cliff,” pharmaceutical companies prevent generic formation through evergreening. Evergreening is the process in which companies artificially extend the lifetime of their ...

Four pharmaceutical companies have filed hundreds of patents ... Legal experts refer to this tactic as “evergreening,” said Stanford University law professor Mark Lemley, who was not involved ...

The case before Judge Collis was about “evergreening”, in which pharmaceutical companies who have patents on medicines extend the life-time of the patent. In the case of rivaroxaban the patent ...

The Global Trade Research Initiative (GTRI) has warned that US President Donald Trump's plan to cut prescription drug prices by 30-80 per cent may lead global pharmaceutical companies to push for ...

Companies also used a strategy called “evergreening,” which is making ... but also allows for plenty of pharma profit,” Merith Basey, executive director of Patients for Affordable Drugs ...

Each year, the U.S. government spends over $100 billion investing in the research and development of new technologies, with pharmaceutical companies being among the chief beneficiaries of this ...